📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Pulmotect

1.1 - Company Overview

Pulmotect Logo

Pulmotect

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of an inhaled therapeutic to prevent and treat respiratory infections. PUL-042 activates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens.

Products and services

  • PUL-042: An inhaled, immune-modulating therapeutic that activates innate lung defenses to protect against viral, bacterial, and fungal pathogens, engineered for prevention of respiratory infections
  • PUL-042 Treatment: An inhaled, pulmonary-targeted product that activates the innate immune system in the lungs to treat respiratory infections caused by viral, bacterial, and fungal pathogens
  • Inhaled Therapeutic Development: Pulmotect develops an inhaled, innate-immunity-activating product to prevent and treat respiratory infections across viral, bacterial, and fungal pathogens

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Pulmotect

Autolus Therapeutics Logo

Autolus Therapeutics

HQ: United Kingdom Website
  • Description: Provider of next-generation programmed T cell therapies for cancer, leveraging T-cell programming and manufacturing technology. Pipeline includes CAR T products such as obe-cel (obecabtagene autoleucel) for adult ALL; AUTO1/22 for pediatric ALL; AUTO4 (TRBC1) and AUTO5 (TRBC2) for peripheral T-cell lymphoma; AUTO6NG (GD2) for neuroblastoma and other solid tumors; and AUTO8 (BCMA/CD19) for multiple myeloma.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Autolus Therapeutics company profile →
Cue Biopharma Logo

Cue Biopharma

HQ: United States Website
  • Description: Provider of biologic immunotherapies and a platform for cancer, chronic viral infections, and autoimmune diseases. Offerings include CUE-101 activating tumor-specific T cells against HPV16+ head and neck cancer; CUE-102/103 targeting additional tumor antigens and HLA alleles in solid tumors; CUE-200 activating virus-specific CD8+ T cells; CUE-300 inhibiting autoreactive CD4+ and enhancing regulatory T cells; CUE-301 for type 1 diabetes.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cue Biopharma company profile →
Eureka Therapeutics Logo

Eureka Therapeutics

HQ: United States Website
  • Description: Provider of T-cell therapies via the ARTEMIS Cell Receptor Platform to engineer T cells to target and destroy cancer cells; the E-ALPHA Phage Display Platform to generate specific antibodies against cancer targets, including TCR-mimic antibodies for solid tumors; and an Expanded Access Policy offering investigational cell therapy under certain conditions to patients with serious or life-threatening diseases who have no other treatment options.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Eureka Therapeutics company profile →
NexImmune Logo

NexImmune

HQ: United States Website
  • Description: Provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NexImmune company profile →
Replimune Logo

Replimune

HQ: United States Website
  • Description: Provider of next-generation oncolytic immunotherapies for cancer, developing proprietary products that enhance direct anti-tumor effects of selective virus replication and boost immune responses to tumor antigens. Products include RP1 (HSV-1 strain with immune-activating transgenes), RP2 (anti-CTLA-4 antibody targeting immunologically silent tumors to enhance tumor killing and immune response), and RP3 (CD40L and 4-1BBL ligands).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Replimune company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Pulmotect

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Pulmotect

2.2 - Growth funds investing in similar companies to Pulmotect

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Pulmotect

4.2 - Public trading comparable groups for Pulmotect

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Pulmotect

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Pulmotect

What does Pulmotect do?

Pulmotect is a provider of an inhaled therapeutic to prevent and treat respiratory infections. PUL-042 activates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens.

Who are Pulmotect's competitors?

Pulmotect's competitors and similar companies include Autolus Therapeutics, Cue Biopharma, Eureka Therapeutics, NexImmune, and Replimune.

Where is Pulmotect headquartered?

Pulmotect is headquartered in United States.

How many employees does Pulmotect have?

Pulmotect has 1,000 employees 🔒.

When was Pulmotect founded?

Pulmotect was founded in 2010 🔒.

What sector and industry vertical is Pulmotect in?

Pulmotect is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Pulmotect

Who are the top strategic acquirers in Pulmotect's sector and industry

Top strategic M&A buyers and acquirers in Pulmotect's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Pulmotect?

Top strategic M&A buyers groups and sectors for Pulmotect include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Pulmotect's sector and industry vertical

Which are the top PE firms investing in Pulmotect's sector and industry vertical?

Top PE firms investing in Pulmotect's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Pulmotect's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Pulmotect's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Pulmotect's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Pulmotect include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Pulmotect's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Pulmotect?

The key public trading comparables and valuation benchmarks for Pulmotect include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Pulmotect for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Pulmotect with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Pulmotect's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Pulmotect with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Pulmotect's' sector and industry vertical?

Access recent funding rounds and capital raises in Pulmotect's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Pulmotect